Home » Stocks » Passage Bio

Passage Bio, Inc. (PASG)

Stock Price: $26.15 USD 0.07 (0.27%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 1.19B
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 45.35M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 2, 2020
Last Price $26.15
Previous Close $26.08
Change ($) 0.07
Change (%) 0.27%
Day's Open 26.34
Day's Range 25.58 - 27.63
Day's Volume 69,182
52-Week Range 8.09 - 38.23

More Stats

Market Cap 1.19B
Enterprise Value 819.09M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 45.35M
Float 17.10M
EPS (basic) n/a
EPS (diluted) n/a
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 616,877
Short Ratio 3.84
Short % of Float 2.24%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 3.95
Revenue n/a
Operating Income n/a
Net Income n/a
Free Cash Flow n/a
Net Cash 366.83M
Net Cash / Share 8.09
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -21.63%
ROE -44.46%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (4)

Buy 3
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(8.99% upside)
Current: 26.15
Target: 28.50
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-37.19-13.47
Net Income-45.63-12.77
Shares Outstanding4.243.60
Earnings Per Share-10.77-3.55
Operating Cash Flow-39.90-18.57
Capital Expenditures-1.19-0.03
Free Cash Flow-41.09-18.60
Cash & Equivalents15924.86
Net Cash / Debt15924.86
Book Value-56.25-12.17
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Passage Bio, Inc.
Country United States
Employees 20
CEO Bruce A. Goldsmith

Stock Information

Ticker Symbol PASG
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: PASG


Passage Bio, Inc., a genetic medicines company, focuses on developing transformative therapies for rare monogenic central nervous system (CNS) diseases. It has research, collaboration, and license agreement with the University of Pennsylvania and its gene therapy program; and The Trustees of the University of Pennsylvania for research and development collaborations, and exclusive license rights to patents for certain products and technologies. The company was founded in 2017 and is based in Philadelphia, Pennsylvania.